Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients

NCT ID: NCT02400255

Last Updated: 2023-12-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-30
• Study Completion Date: 2022-05-31

Brief Summary

This is a single-arm, Phase II study of crenolanib as maintenance in AML patients with FLT3 mutations who have achieved complete remission (CR) after allogeneic stem cell transplantation. Oral crenolanib will be administered daily post-transplant for up to two years.

Detailed Description

There are two patient subgroups: 1) those who were in complete remission (CR) at the time of transplant, and 2) those who were not in complete remission (NCR) at the time of transplant. Start of crenolanib therapy at 100 mg TID is intended at the earliest time no sooner than 42 days but no later than 90 days after allogeneic stem cell transplantation. Patients may take crenolanib continuously for up to 728 days or until one of the criteria for study discontinuation is fulfilled.

Conditions

Acute Myeloid Leukemia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort A

Cohort A will include patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) while in first or second complete remission with count recovery. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 42 days but no later than 90 days after allogeneic HSCT.

Group Type: EXPERIMENTAL

Crenolanib besylate

Intervention Type: DRUG

Cohort B

Cohort B will include patients who underwent HSCT with incomplete count recovery although they had ≤%10 bone marrow blasts at the time of HSCT. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 42 days but no later than 90 days after allogeneic HSCT.

Group Type: EXPERIMENTAL

Crenolanib besylate

Intervention Type: DRUG

Interventions

Crenolanib besylate

Intervention Type: DRUG

Other Intervention Names

CP-868,596-26

Eligibility Criteria

Inclusion Criteria

1. History of AML according to World Health Organization (WHO) classification

2. First allogeneic hematopoietic stem cell transplantation (HSCT) using myeloablative conditioning (MAC), non-myeloablative (NMA), or reduced-intensity conditioning (RIC) preparative regimens.

3. FLT3-ITD or FLT3-D835 positive disease at any time during disease course.

4. Hematopoietic stem cell source is either with peripheral blood, bone marrow or cord blood.

5. Donor source is matched related, unrelated, haploidentical donor or cord blood.

6. At the time of allogeneic HSCT:

1. No more than 1 antigen mismatch at HLA-A, -B, -C, -DRB1 or -DQB1 locus for unrelated donor with peripheral blood and bone marrow as the hematopoietic stem cell source; and

2. Bone marrow blast ≤ 10%

7. No sooner than 42 days but no later than 90 days after allogeneic HSCT.

8. Post-transplant bone marrow blast count ≤ 5% confirmed within 21 days (+4 days) prior to starting study therapy

9. Evidence of donor engraftment as defined by institutional standard T cell chimerism > 50%.

10. Adequate engraftment within 7 days prior to starting study therapy: ANC ≥ 1.0 x 10^9/L without daily use of myeloid growth factor; and platelet ≥ 25 x 10^9/L without platelet transfusion within 1 week

11. Non-hematological toxicities ≤ Grade 2

12. Serum creatinine ≤ 1.5 × ULN OR creatinine clearance ≥ 50mL/min/1.73 m2 for subjects with creatinine levels above institutional normal

13. Adequate liver function with serum AST, ALT and bilirubin within the normal range at the time of crenolanib commencement

14. Acute graft-versus-host disease (GVHD) ≤ Grade 1, either no signs of chronic GVHD or mild chronic GVHD graded as limited disease

15. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

16. Age ≥ 18 years with the capacity to give written informed consent

17. Non-pregnant and non-nursing women of childbearing potential must have a negative serum or urine pregnancy test ("Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months)

18. Women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and for 90 days following completion of therapy

Exclusion Criteria

1. Bone marrow blast >5% within 21 days (+4 days) of start of study drug

2. Active GVHD grade ≥ 2

3. Concurrent use of corticosteroids equivalent of prednisone at a dose > 0.5 mg/kg

4. Active and/or untreated central nervous system (CNS) leukemia

5. Concomitant therapies for treatment or control of leukemia.

6. Use of any of the following after transplantation and prior to starting study therapy:

1. Chemotherapeutic agents for therapy of AML (note that prophylactic use of these agents is allowed in this study, e.g., methotrexate for GVHD)

2. Investigational agents/therapies

3. Azacitidine, decitabine or other demethylating agents

4. Lenalidomide, thalidomide and pomalidomide

7. Uncontrolled infection

8. Known positive for human immunodeficiency virus (HIV); active hepatitis B (HBV) or hepatitis C (HCV) infection

9. Significant cardiac disease (New York Heart Association classes III or IV) or unstable angina despite medication

10. Pregnant or breast-feeding

11. Major surgery within 4 weeks of starting study drug

12. Receipt of investigational agents within 5 half-lives of last dose of investigational agent

13. Prior treatment with crenolanib with progression on treatment

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Arog Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Richard Champlin, MD

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

MD Anderson Cancer Center

Houston, Texas, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

ARO-009

Identifier Type: -

Identifier Source: org_study_id